These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 36941602)

  • 21. Exostoisns (EXT1/2) in Head and Neck Cancers: An In Silico Analysis and Clinical Correlates.
    Wang Y; Huang Y; Zhu H; Guo Z; Cheng J; Zhang C; Zhong M
    Int Dent J; 2024 Jun; 74(3):446-453. PubMed ID: 37989698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma.
    Gao W; Zhang ZW; Wang HY; Li XD; Peng WT; Guan HY; Liao YX; Liu A
    Front Genet; 2022; 13():895281. PubMed ID: 35754792
    [No Abstract]   [Full Text] [Related]  

  • 23. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
    Chen Y
    Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
    Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
    Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
    Hu Y; Chen J; Liu M; Feng Q; Peng H
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma.
    Yang ML; Zhang JH; Li S; Zhu R; Wang L
    Pathol Oncol Res; 2021; 27():1609967. PubMed ID: 34840533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
    Yin Z; Ma T; Chen S; Yu M
    Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Dai Y; Chen W; Huang J; Cui T
    Biomed Res Int; 2021; 2021():8874578. PubMed ID: 34285919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
    Li Y; Liu H
    Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of the prognosis and biological significance of ROR
    Zheng J; Tang H; Yang Y; Yang K
    Environ Toxicol; 2024 Feb; 39(2):487-508. PubMed ID: 37278231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiles of immune cell infiltration in head and neck squamous carcinoma.
    Liang B; Tao Y; Wang T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRGBP: A New Factor for Diagnosis and Prediction of Head and Neck Squamous Cell Carcinoma.
    Zhao C; Wei C; Chen X; Li P
    Biomed Res Int; 2022; 2022():7281120. PubMed ID: 35924262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
    Gong X; Ren F
    Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer.
    Shen Y; Wei Z; Zhou C; Song J; Wang J; Wang J; Wu L; Fang S; Shen Z
    J Clin Lab Anal; 2022 Sep; 36(9):e24600. PubMed ID: 35870182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
    Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
    [No Abstract]   [Full Text] [Related]  

  • 40. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
    Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
    PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.